LY3526318 + Placebo

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diabetic Peripheral Neuropathic Pain

Conditions

Diabetic Peripheral Neuropathic Pain

Trial Timeline

Jan 26, 2022 → Oct 13, 2022

NCT ID

NCT05177094

About LY3526318 + Placebo

LY3526318 + Placebo is a phase 2 stage product being developed by Eli Lilly for Diabetic Peripheral Neuropathic Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT05177094. Target conditions include Diabetic Peripheral Neuropathic Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05177094	Phase 2	Completed	Jan 26, 2022	Oct 13, 2022	Diabetic Peripheral Neuropathic Pain
NCT05086289	Phase 2	Completed	Oct 25, 2021	Jun 17, 2022	Chronic Low-back Pain
NCT05080660	Phase 2	Completed	Oct 12, 2021	Jun 6, 2022	Osteoarthritis
NCT04682119	Phase 1	Completed	Dec 29, 2020	Apr 21, 2021	Healthy
NCT04183283	Phase 1	Completed	Dec 12, 2019	Mar 6, 2020	Healthy
NCT03977974	Phase 1	Terminated	Jun 21, 2019	Mar 5, 2020	Healthy

Competing Products

20 competing products in Diabetic Peripheral Neuropathic Pain

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	44
CHF6467 active	Comac Medical	Phase 1/2	33
Ruboxistaurin mesylate	Eli Lilly	Phase 3	77
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	47
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	28
Baricitinib + Placebo	Eli Lilly	Phase 2	52
LY3857210 + Placebo	Eli Lilly	Phase 2	52
UBX1325	Unity Biotechnology	Phase 2	44
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	44
UBX1325	Unity Biotechnology	Phase 1	25
CT-P42 + Eylea	Celltrion	Phase 3	77
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	85
Anplag(Sarpogrelate) + Placebo	Yuhan	Approved	85
CS-3150 + placebo	Daiichi Sankyo	Phase 2	52
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	52
olmesartan medoxomil + Placebo Tablets	Daiichi Sankyo	Phase 3	77
DS-5565 + placebo	Daiichi Sankyo	Phase 3	77
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	77
DS-5565	Daiichi Sankyo	Phase 3	77
Beraprost sodium	Astellas Pharma	Pre-clinical	23

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved